Inhibition of the histamine-induced weal and flare response: A valid surrogate measure for antihistamine clinical efficacy?

Clinical and Experimental Allergy

Volumn 37, Issue 3, 2007, Pages 400-414

  Devillier, P ^a   Bousquet, J ^b  

^a FOCH HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ASTEMIZOLE; BETOTASTINE; CETIRIZINE; CHLORPHENIRAMINE; CYPROHEPTADINE; DESLORATADINE; EBASTINE; EPINASTINE; FEXOFENADINE; HISTAMINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; OLOPATADINE; PLACEBO; PROMETHAZINE; TERFENADINE;

ALLERGIC REACTION; ALLERGIC RHINITIS; BIOASSAY; CHRONIC URTICARIA; CLINICAL PRACTICE; DATA EXTRACTION; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG INHIBITION; HUMAN; LITERATURE; MEASUREMENT; METHODOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SKIN TEST; SYSTEMATIC REVIEW; URTICARIA;

ALLERGENS; ANTI-ALLERGIC AGENTS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; RHINITIS, ALLERGIC, SEASONAL; SKIN TESTS; URTICARIA;

EID: 33847771905     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02662.x     Document Type: Review

References (142)

1. Salib RJ, Drake-Lee A, Howarth PH. Allergic rhinitis: past, present and the future. Clin Otolaryngol 2003; 28:291-303.
2. Bousquet J, Neukirch F, Bousquet PJ et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006; 117:158-62.
3. Dykewicz MS, Fineman S, Skoner DP et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81:478-518.
4. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med 2000; 162:1391-6.
5. European Academy of Allergology and Clinical Immunology. The impact of allergic rhinitis on quality of life and other airway diseases. Summary of a European conference. Allergy 1998; 53 (Suppl. 41):7-31.
6. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004; 22:345-61.
7. Bousquet J, Van Cauwenberge P, Khaltaev NAria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl.):S147-S334.
8. Baiardini I, Pasquali M, Braido F et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy 2005; 60:1073-8.
9. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
10. Greaves M. Chronic urticaria. J Allergy Clinical Immunol 2000; 105:664-72.
11. Baroody FM. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 2003; 128:616-31.
12. Lee B-J, Naclerio RM, Bochner BS, Taylor RM, Lin MC, Baroody FM. Nasal challenge with allergen upregulates the local expression of vascular endothelial adhesion molecules. J Allergy Clin Immunol 1999; 94:1006-16.
13. D'Andrea MR, Derian CK, Leturcq D et al. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem 1998; 46:157-64.
14. Bez C, Schubert R, Kopp M et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy 2004; 34:1079-85.
15. Rauter I, Krauth M-T, Flicker S et al. Allergen cleavage by effector cell-derived protease regulates allergic inflammation. FASEB J 2006; 20:E61-9.
16. 2LEN/EDF guidelines: management of urticaria. Allergy 2006; 61:321-31.
17. Bousquet J, Bindslev-Jensen C, Canonica GW et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004; 59 (Suppl. 77):4-16.
18. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99:S798-806.
19. Petersen LJ, Church MK, Rihoux JP, Skov PS. Measurement of interstitial cetirizine concentrations in human skin: correlation of drug levels with inhibition of histamine-induced skin responses. Allergy 1999; 54:607-11.
20. 1-receptor antagonists in skin and serum. J Allergy Clin Immunol 1995; 95:759-64.
21. Deschamps C, Dubruc C, Mentre F, Rosenzweig P. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model. Clin Pharmacol Ther 2000; 68:647-57.
22. Howarth PH. Assessment of antihistamine efficacy and potency. Clin Exp Allergy 1999; 29 (Suppl. 3):87-97.
23. Magerl W, Westerman RA, Mohner B, Handwerker HO. Properties of transdermal histamine iontophoresis: differential effects of season, gender, and body region. J Invest Dermatol 1990; 94:347-52.
24. Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and neuropeptide release in human skin as measured by intradermal microdialysis. Neurosci Lett 1997; 230:117-20.
25. Petersen LJ, Church MK, Skov PS. Histamine is released in the wheal but not the flare following challenge of human skin in vivo: a microdialysis study. Clin Exp Allergy 1997; 27:284-95.
26. Demoly P, Bousquet J, Manderscheid J-C, Dreborg S, Dhivert H, Michel F-B. Precision of skin prick and puncture tests with nine methods. J Allergy Clin Immunol 1991; 88:758-62.
27. DeWeck AL, Derer T, Bähre M. Investigation of the anti-allergic activity of azelastine on the immediate and late-phase reactions to allergens and histamine using telethermography. Clin Exp Allergy 2000; 30:283-7.
28. Hammarlund A, Olsson P, Pipkorn U. Blood flow in dermal allergen-induced immediate and late-phase reactions. Clin Exp Allergy 1989; 19:197-202.
29. Olsson P, Hammarlund A, Pipkorn U. Wheal-and-flare reactions induced by allergen and histamine: evaluation of blood flow with laser Doppler flowmetry. J Allergy Clin Immunol 1988; 82:291-6.
30. Hammarlund A, Olsson P, Pipkorn U. Blood flow in histamine- and allergen-induced weal and flare responses, effects of an H1 antagonist, alpha-adrenoceptor agonist and a topical glucocorticoid. Allergy 1990; 45:64-70.
31. Carr WW, Martin B, Howard RS, Cox L, Borish Land the Immunotherapy Committee of the American Academy of Allergy, Asthma and Immunology. Comparison of test devices for skin prick testing. J Allergy Clin Immunol 2005; 116:341-6.
32. Nelson HS, Knoetzer J, Bucher B. Effect of distance between sites and region of the body on results of skin prick tests. J Allergy Clin Immunol 1996; 97:596-601.
33. Kalogeromitros D, Katsarou A, Armenaka M, Rigopoulos D, Zapanti M, Stratigos I. Influence of the menstrual cycle on skin-prick test reactions to histamine, morphine and allergen. Clin Exp Allergy 1995; 25:461-6.
34. Lee RE, Smolensky MH, Leach CS, McGovern JP. Circadian rhythms in the cutaneous reactivity to histamine and selected antigens, including phase relationship to urinary cortisol excretion. Ann Allergy 1977; 38:231-6.
35. Haahtela T, Jokela H. Influence of the pollen season on immediate skin test reactivity to common allergens. Allergy 1980; 35:15-21.
36. Spiewak R. Inter-individual and intra-individual variability of skin reactivity to histamine at prick testing. Dermatol Online J 1995; 1:4.
37. Carey W, Warrington S, Boyce M, Luria X. Inhibition of the histamine wheal by ebastine compared with cetirizine, fexofenadine and loratadine at steady state. Drugs Exp Clin Res 2002; 28:243-7.
38. Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 2001; 56:985-8.
39. Denham KJ, Boutsiouki P, Clough GF, Church MK. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003; 52:424-7.
40. Roman IJ, Kassem N, Gural RP, Herron J. Suppression of histamine-induced wheal response by loratadine (SCH 29851) over 28 days in man. Ann Allergy 1986; 57:253-6.
41. Rosenzweig P, Caplain H, Chaufour S, Ulliac N, Cabanis MJ, Thebault JJ. Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995; 40:459-65.
42. Humphreys F, Hunter JA. The effects of astemizole, cetirizine and loratadine on the time course of wheal and flare reactions to histamine, codeine and antigen. Br J Dermatol 1991; 125:364-7.
43. Barbanoj MJ, Antonijoan RM, García-Gea C et al. A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity. Int Arch Allergy Immunol 2003; 132:263-7.
44. Gispert J, Antonijoan R, Barbanoj M et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutaneous challenges. Ann Allergy Asthma Immunol 2002; 89:259-64.
45. Lever LR, Hill S, Marks R, Rosenberg R, Thompson D. Effects of cetirizine, loratadine and terfenadine on histamine weal and flare reactions. Skin Pharmacol 1992; 5:29-33.
46. Pechadre JC, Vernay D, Trolese JF, Bloom M, Dupont P, Rihoux JP. Comparison of the central and peripheral effects of cetirizine and terfenadine. Eur J Clin Pharmacol 1988; 35:255-9.
47. Rihoux JP, Van Neste DJ. Quantitative time course study of the skin response to histamine and the effect of H1 blockers. A 3-week crossover double-blind comparative trial of cetirizine and terfenadine. Dermatologica 1989; 179:129-34.
48. Kontou-Fili K, Paleologos G, Herakleous M. Suppression of histamine-induced skin reactions by loratadine and cetirizine diHCl. Eur J Clin Pharmacol 1989; 36:617-9.
49. Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS. A standardized, quantitative skin-test assay of allergen potency and stability: studies on the allergen dose-response curve and effect of wheal, erythema, and patient selection on assay results. J Allergy Clin Immunol 1982; 70:343-52.
50. Squire JR. The relationship between horse dandruff and horse serum antigen in asthma. Clin Sci 1950; 9:127-50.
51. Frossard N, Benabdesselam O, Purohit A, Mounedji N, Pauli G. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady state treatment in the skin of healthy volunteers. Fundam Clin Pharmacol 2000; 14:409-13.
52. Purohit A, Mélac M, Pauli G, Frossard N. Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h. Br J Clin Pharmacol 2002; 53:250-4.
53. Town GI, Holgate ST. Comparison of the effect of loratadine on the airway and skin responses to histamine, methacholine, and allergen in subjects with asthma. J Allergy Clin Immunol 1990; 86:886-93.
54. Devalia JL, Hanotte F, Baltes E, De Vos C. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56:50-57.
55. Grant JA, Danielson L, Rihoux J-P, DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999; 54:700-7.
56. Grant JA, Riethuisen J-M, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88:190-7.
57. Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17:241-55.
58. Purohit A, Duvernelle C, Mélac M, Pauli G, Frossard N. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001; 86:387-92.
59. Purohit A, Mélac M, Pauli G, Frossard N. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56:388-94.
60. Purohit A, Mélac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol 2004; 92:635-40.
61. Purohit A, N'Gom AS, Deslandes B, Pauli G, Frossard N. Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol 2004; 93:562-7.
62. Fadel R, Herpin-Richard N, Dufresne F, Rihoux JP. Pharmacological modulation by cetirizine and loratadine of antigen and histamine-induced skin weals and flares, and late accumulation of eosinophils. J Int Med Res 1990; 18:366-71.
63. Basomba A. Evaluation of changes in skin sensitivity by means of skin tests. EACCI '93 subcommittee on skin tests. Allergy 1993; 48:71-75.
64. Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol 2004; 29:526-32.
65. Wang RQ, Zhang HY. Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004; 26:634-8.
66. Kaliner MA, White MV, Economides A et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol 2003; 90:629-34.
67. Shall L, Thompson DA, Barkley AS, Millard LG. Comparative inhibition profiles of three non-sedating antihistamines assessed by an extended Lewis model. Clin Exp Allergy 1992; 22:711-6.
68. Van Neste D, Coussement C, Ghys L, Rihoux JP. Agonist-antagonist interactions in the skin: comparison of effects of loratadine and cetirizine on skin vascular responses to prick tests with histamine and substance P. J Dermatol Sci 1992; 4:172-9.
69. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990; 86:540-7.
70. Bayramgürler D, Bilen N, Apaydýn R et al. Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses. Clin Exp Dermatol 1999; 24:407-11.
71. Leroy T, Tasset C, Valentin B, Van Neste D. Comparison of the effects of cetirizine and ebastine on the skin response to histamine iontophoresis monitored with laser Doppler flowmetry. Dermatology 1998; 197:146-51.
72. Roongapinun S, Wajajamreon S, Fooanant S. Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy. J Med Assoc Thailand 2004; 87:551-6.
73. 1-antihistaminic activity of cetirizine and fexofenadine in allergic children. Pediatr Allergy Immunol 2003; 14:207-11.
74. 1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy 2002; 57:346-50.
75. 1-receptor antagonists cetirizine and loratadine in children. Pediatr Allergy Immunol 2000; 11:116-9.
76. Persi L, Demoly P, Harris AG, Tisserand B, Michel F-B, Bousquet J. Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine. J Allergy Clin Immunol 1999; 103:591-4.
77. Bousquet J, Czarlewski W, Cougnard J, Danzig M, Michel FB. Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis. Allergy 1998; 53:579-85.
78. Hamilton SA, Duddle J, Herdman MJ, Trigg CJ, Davies RJ. Comparison of a new antihistaminic and antiallergic compound KW 4679 with terfenadine and placebo on skin and nasal provocation in atopic individuals. Clin Exp Allergy 1994; 24:955-9.
79. Passalacqua G, Guerra L, Compalati E et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol 2004; 135:143-7.
80. Sienra-Monge JJ, Gazca-Aguilar A, Del Rio-Navarro B. Double-blind comparison of cetirizine and loratadine in children ages 2 to 6 years with perennial allergic rhinitis. Am J Ther 1999; 6:149-55.
81. Berkowitz RB, Dockhorn R, Lockey R et al. Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Ann Allergy Asthma Immunol 1996; 76:363-8.
82. Leynadier F, Duarte-Risselin C, Murrieta M, for the URTILOR Study Group. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. Eur J Dermatol 2000; 10:205-11.
83. Villas Martinez F, Contreras FJ, Lopez Cazana JM, Lopez Serrano MC, Martinez Alzamora F. A comparison of new nonsedating and classical antihistamines in the treatment of primary acquired cold urticaria (ACU). J Invest Allergol Clin Immunol 1992; 2:258-62.
84. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not purely a histamine-related disease. Allergy 2000; 55 (Suppl. 64):7-16.
85. Charlesworth EN, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989; 83:905-12.
86. De Vos C. H1 antagonists and inhibitors of eosinophil accumulation. Clin Exp Allergy 1991; 21 (Suppl. 1):277-81.
87. Walsh GM, Moqbel R, Hartnell A, Kay AB. Effects of cetirizine on human eosinophil and neutrophil activation in vitro. Int Arch Allergy Appl Immunol 1991; 95:158-62.
88. Klementsson H, Andersson M, Pipkorn U. Allergen-induced increase in nonspecific nasal reactivity is blocked by antihistamines without a clear-cut relationship to eosinophil influx. J Allergy Clin Immunol 1990; 86:466-72.
89. Raphael GD, Angello JT, Wu M-M, Druce HM. Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006; 96:606-14.
90. Ciprandi G, Cirillo I, Vizzaccaro A et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol 2005; 5:1800-8.
91. Hyo S, Fujieda S, Kawada R, Kitazawa S, Takenaka H. The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. Ann Allergy Asthma Immunol 2005; 94:457-64.
92. Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004; 20:891-902.
93. Hampel F Jr, Howland W III, Van Bavel J, Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10mg once daily in the treatment of seasonal allergic rhinitis. J Invest Allergol Clin Immunol 2004; 14:56-63.
94. Ratner P, Hampel F Jr, Van Bavel J, Howland WIII. Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Int Arch Allergy Immunol 2004; 133:371-9.
95. Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003; 25:1975-87.
96. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32:1504-9.
97. Frèche C, Leynadier F, Horak F et al. Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. Ann Allergy Asthma Immunol 2002; 89:304-10.
98. Ratner PH, Lim JC, Georges GC, and the Ebastine Study Group. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 105:1101-7.
99. Nunes C, Ladeira S. Double-blind study of cetirizine and loratadine versus placebo in patients with allergic rhinitis. Invest Allergol Clin Immunol 2000; 10:20-23.
100. van Cauwenberge P, Juniper EF, and the STAR Study Investigating Group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30:891-9.
101. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104:927-33.
102. Sabbah A, Daele J, Wade AG, Ben-Soussen P, Attali P, and the MIZOCET Study Group. Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol 1999; 83:319-25.
103. Druce HM, Thoden WR, Mure P et al. Brompheniramine, loratadine, and placebo in allergic rhinitis: a placebo-controlled comparative clinical trial. J Clin Pharmacol 1998; 38:382-9.
104. Lockey RF, Widlitz MD, Mitchell DQ et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996; 76:448-54.
105. Del Carpio J, Kabbash L, Turenne Y et al. Efficacy and safety of loratadine (10mg once daily), terfenadine (60 mg twice daily), and placebo in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1989; 84:741-6.
106. Horak F, Bruttmann G, Pedrali P et al. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung 1988; 38:124-8.
107. Skassia-Brociek W, Bousquet J, Montes F et al. Double-blind placebo-controlled study of loratadine, mequitazine, and placebo on the symptomatic treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1988; 81:725-30.
108. Buckley CE, Buchman E, Falliers CJ et al. Terfenadine treatment of fall hay fever. Ann Allergy 1988; 60:123-8.
109. Oei HD. Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action. Ann Allergy 1988; 61:436-9.
110. Dockhorn RJ, Bergner A, Connell JT et al. Safety and efficacy of loratadine (Sch-29851): a new non-sedating antihistamine in seasonal allergic rhinitis. Ann Allergy 1987; 58:407-11.
111. Kemp JP, Bahna SL, Chervinsky P et al. A comparison of loratadine, a new nonsedating antihistamine, with clemastine and placebo in patients with fall seasonal allergic rhinitis. Am J Rhinol 1987; 1:151-4.
112. Kemp JP, Buckley CE, Gershwin ME et al. Multicenter, double-blind, placebo-controlled trial of terfenadine in seasonal allergic rhinitis and conjunctivitis. Ann Allergy 1985; 54:502-9.
113. Corren J, Storms W, for the Azelastine Cetirizine Trial No. 1 (ACT 1) Study Group. et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005; 27:543-53.
114. Martinez-Cócera C, De Molina M, on behalf of the Spanish Rupatadine Rhinitis Study Group. et al. Rupatadine 10mg and cetirizine 10mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J Invest Allergol Clin Immunol 2005; 15:22-29.
115. Horak F, Stübner P, Zieglmayer R et al. Clinical study of the therapeutic efficacy of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. Arzneimittelforschung 2004; 54:666-72.
116. 1 receptor-specific histamine antagonist, to loratadine 10mg in the treatment of seasonal allergic rhinitis. J Invest Allergol Clin Immunol 2004; 14:34-40.
117. Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91:354-61.
118. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000; 22:760-9.
119. Murris-Espin M, Melac M, Charpentier J-C, Didier A. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998; 80:399-403.
120. CrawfordWW, Klaustermeyer WB, Lee PH, Placik IM. Comparative efficacy of terfenadine, loratadine, and astemizole in perennial allergic rhinitis. Otolaryngol Head Neck Surg 1998; 118:668-73.
121. Al-Muhaimeed H. A parallel-group comparison of astemizole and loratadine for the treatment of perennial allergic rhinitis. J Int Med Res 1997; 25:175-81.
122. Bellioni P, Catalano B, Cervellera G, Filiaci F, Mira E, Carraro A. Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996; 34:101-4.
123. Gehanno P, Bremard-Oury C, Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 1996; 76:507-12.
124. Harcup JW, Hawkes G, Saul PA. The efficacy and sedative profile of astemizole and cetirizine in the treatment of grass pollen hay fever in general practice. Br J Clin Pract 1993; 47:131-5.
125. Lockey RF, Findley S, Mitchell DQ, Woehler T, Lieberman P, Nicodemus CF. Effects of cetirizine versus terfenadine in seasonal allergic rhinitis. Ann Allergy 1993; 70:311-5.
126. Olsen OT, Nüchel Petersen L, Høi L, Lorentzen KA, Hindberg Rasmussen W, Svendsen UG. Comparison of loratadine and terfenadine in allergic seasonal rhinoconjunctivitis with emphasis on nasal stuffiness and peak flow. Arzneimittelforschung 1992; 42:1227-31.
127. Caiaffa MF, Iudice A, Macchia L et al. Multicenter double-blind comparative study of terfenadine and cetirizine in hay fever. J Invest Allergol Clin Immunol 1992; 2:162-6.
128. Davies BH. Prophylactic treatment of seasonal allergic rhinitis. Clin Ther 1991; 13:87-91.
129. Katelaris C. Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pacific J Allergy Immunol 1990; 8:103-7.
130. Backhouse CI, Renton R, Fidler C, Rosenberg RM. Multicentre double-blind comparison of terfenadine and cetirizine in patients with seasonal allergic rhinitis. Br J Clin Pract 1990; 44:88-91.
131. Rijntjes E, Ghys L, Rihoux J-P. Astemizole and cetirizine in the treatment of seasonal allergic rhinitis: a comparative double-blind, multicentre study. J Int Med Res 1990; 18:219-24.
132. Davies BH, Mullins J, Couch HA. Prophylactic treatment of seasonal allergic rhinitis. A comparison of cetirizine (Zirtek) and terfenadine (Triludan). Clin Trials J 1989; 26:100-7.
133. Backhouse CI, Rosenberg R. Prophylaxis of whole season hay fever symptomatology: a comparison of terfenadine with chlorpheniramine. Br J Clin Pract 1987; 41:995-9.
134. Morita E, Matsuo H, Zhang Y. Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis. J Dermatol 2005; 32:58-61.
135. Dubertret L, Murrieta Aguttes M, Tonet J, and the MILOR Study Group. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR study. J Eur Acad Dermatol Venereol 1999; 12:16-24.
136. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996; 30:1075-9.
137. Belaich S, Bruttmann G, DeGreef H et al. Comparative effects of loratadine and terfenadine in the treatment of chronic idiopathic urticaria. Ann Allergy 1990; 64:191-4.
138. Grant JA, Bernstein DI, Buckley CE et al. Double blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1988; 81:574-9.
139. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatol Treat 2004; 15:55-57.
140. La Rosa M, Leonardi S, Marchese G et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001; 87:48-53.
141. Alomar A, De La Cuarda J, Fernandez J. Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria. J Int Med Res 1990; 18:358-65.
142. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med 2005; 353:1934-44.